Blood: 132 (14)

BLOOD COMMENTARIES

Red Cells, Iron, and Erythropoiesis

You have access
A long sought after “receptor” for ERFE?
An-Sheng Zhang and Caroline A. Enns

Blood 2018 132:1463-1464; doi: https://doi.org/10.1182/blood-2018-08-869586
Lymphoid Neoplasia

You have access
M-protein–related disorders: MGCS
Joan Bladé and M. Teresa Cibeira

Blood 2018 132:1464-1465; doi: https://doi.org/10.1182/blood-2018-07-865642
Clinical Trials and Observations

You have access
Next-generation therapy for follicular lymphoma
Loretta J. Nastoupil

Blood 2018 132:1465-1467; doi: https://doi.org/10.1182/blood-2018-08-868117
Immunobiology and Immunotherapy

You have access
Getting the most from your CAR target
David M. Barrett

Blood 2018 132:1467-1468; doi: https://doi.org/10.1182/blood-2018-08-869552
Myeloid Neoplasia

You have access
MBD4: guardian of the epigenetic galaxy
Lambert Busque and Lucy A. Godley

Blood 2018 132:1468-1469; doi: https://doi.org/10.1182/blood-2018-08-867044
Myeloid Neoplasia

You have access
Mice no longer immune to immunomodulatory drugs
Flavia Pichiorri

Blood 2018 132:1470-1471; doi: https://doi.org/10.1182/blood-2018-08-868083

PLENARY PAPER

Red Cells, Iron, and Erythropoiesis

You have access
Erythroferrone inhibits the induction of hepcidin by BMP6
João Arezes, Niall Foy, Kirsty McHugh, Anagha Sawant, Doris Quinkert, Virginie Terraube, Alette Brinth, May Tam, Edward R. LaVallie, Stephen Taylor, Andrew E. Armitage, Sant-Rayn Pasricha, Orla Cunningham, Matthew Lambert, Simon J. Draper, Reema Jasuja and Hal Drakesmith

Blood 2018 132:1473-1477; doi: https://doi.org/10.1182/blood-2018-06-857995

SPECIAL REPORT

You have access
Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications
Jean-Paul Fermand, Frank Bridoux, Angela Dispenzieri, Arnaud Jaccard, Robert A. Kyle, Nelson Leung and Giampaolo Merlini

Blood 2018 132:1478-1485; doi: https://doi.org/10.1182/blood-2018-04-839480

CLINICAL TRIALS AND OBSERVATIONS

$An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma$

You have access
An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma
Franck Morschhauser, Gilles Salles, Steven Le Gouill, Herve Tilly, Catherine Thieblemont, Krimo Bouabdallah, Bettina Fabiani, Cédric Ménard, Karin Tarte, Guillaume Cartron and Roch Houot

Blood 2018 132:1486-1494; doi: https://doi.org/10.1182/blood-2018-05-853499

IMMUNOBIOLOGY AND IMMUNOTHERAPY

You have access
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas
Irene Scarfò, Maria Ormhøj, Matthew J. Frigault, Ana P. Castano, Selena Lorrey, Amanda A. Bouffard, Alexandria van Scoyk, Scott J. Rodig, Alexandra J. Shay, Jon C. Aster, Frederic I. Preffer, David M. Weinstock and Marcela V. Maus

Blood 2018 132:1495-1506; doi: https://doi.org/10.1182/blood-2018-04-842708

LYMPHOID NEOPLASIA

You have access
North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies
Urvi A. Shah, Elaine Y. Chung, Orsi Giricz, Kith Pradhan, Keisuke Kataoka, Shanisha Gordon-Mitchell, Tushar D. Bhagat, Yun Mai, Yongqiang Wei, Elise Ishida, Gaurav S. Choudhary, Ancy Joseph, Ronald Rice, Nadege Gitego, Crystall Parrish, Matthias Bartenstein, Swati Goel, Ioannis Mantzaris, Aditi Shastri, Olga Derman, Adam Binder, Kira Gritsman, Noah Kornblum, Ira Braunschweig, Chirag Bhagat, Jeff Hall, Armin Graber, Lee Ratner, Yanhua Wang, Seishi Ogawa, Amit Verma, B. Hilda Ye and Murali Janakiram

Blood 2018 132:1507-1518; doi: https://doi.org/10.1182/blood-2018-01-824607
$Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group$

You have access
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group
Dennis A. Eichenauer, Annette Plütschow, Lena Schröder, Michael Fuchs, Boris Böll, Bastian von Tresckow, Volker Diehl, Peter Borchmann and Andreas Engert

Blood 2018 132:1519-1525; doi: https://doi.org/10.1182/blood-2018-02-836437

MYELOID NEOPLASIA

You have access
MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML
Mathijs A. Sanders, Edward Chew, Christoffer Flensburg, Annelieke Zeilemaker, Sarah E. Miller, Adil S. al Hinai, Ashish Bajel, Bram Luiken, Melissa Rijken, Tamara Mclennan, Remco M. Hoogenboezem, François G. Kavelaars, Stefan Fröhling, Marnie E. Blewitt, Eric M. Bindels, Warren S. Alexander, Bob Löwenberg, Andrew W. Roberts, Peter J. M. Valk and Ian J. Majewski

Blood 2018 132:1526-1534; doi: https://doi.org/10.1182/blood-2018-05-852566
You have access
Crbn^I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Emma C. Fink, Marie McConkey, Dylan N. Adams, Saurav D. Haldar, James A. Kennedy, Andrew A. Guirguis, Namrata D. Udeshi, D. R. Mani, Michelle Chen, Brian Liddicoat, Tanya Svinkina, Andrew T. Nguyen, Steven A. Carr and Benjamin L. Ebert

Blood 2018 132:1535-1544; doi: https://doi.org/10.1182/blood-2018-05-852798

BLOOD WORK

You have access
An unexpected association of hematologic malignancies
Nicolas Athanase and Elise Frébet

Blood 2018 132:1545; doi: https://doi.org/10.1182/blood-2018-03-842013

Top Menu

Ash User

Advertisement

Table of Contents

October 04, 2018; 132 (14)

BLOOD COMMENTARIES

PLENARY PAPER

SPECIAL REPORT

CLINICAL TRIALS AND OBSERVATIONS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

BLOOD WORK

Issue Highlights

Advertisement

American Society of Hematology

Information for:

Advertisement

Top Menu

Ash User

Table of Contents

October 04, 2018; 132 (14)

BLOOD COMMENTARIES

PLENARY PAPER

SPECIAL REPORT

CLINICAL TRIALS AND OBSERVATIONS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

BLOOD WORK

Issue Highlights

Jump to

American Society of Hematology

Information for: